SCHEMBL32669369

SCHEMBL32669369

C(=N/Nc1nc(NCCc2ccccn2)nc(N2CCSCC2)n1)\c1c[nH]c2ccccc12

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 11/20 0.58
▸ MEN1 O00255 7/20 0.58
▸ KMT2A Q03164 7/20 0.58
▸ POLB P06746 2/20 0.58
▸ L3MBTL1 Q9Y468 2/20 0.58
▸ GAA P10253 7/20 0.53
▸ LMNA P02545 4/20 0.53
▸ CYP1A2 P05177 2/20 0.53
▸ CYP3A4 P08684 2/20 0.53
▸ CYP2C9 P11712 2/20 0.53
▸ CYP2C19 P33261 2/20 0.53
▸ PIKFYVE Q9Y2I7 1/20 0.53
▸ ALDH1A1 P00352 3/20 0.51
▸ THRB P10828 1/20 0.51
▸ NPSR1 Q6W5P4 1/20 0.51
▸ TDP1 Q9NUW8 3/20 0.46
▸ ATM Q13315 1/20 0.46
▸ RECQL P46063 1/20 0.45
▸ HTR1A P08908 3/20 0.42
▸ DRD2 P14416 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL32669196 0.90 MAPT (0.67) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL32669211 0.83 MAPT (0.70) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL13759143 0.80 MAPT (0.69) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL32669247 0.79 PIKFYVE (0.49) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL3325959 0.78 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL10195928 0.78 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL3088439 0.78 MAPT (0.62) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL23345455 0.77 MAPT (0.81) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL13759054 0.77 MAPT (0.56) MAPTMEN1KMT2APOLBL3MBTL1
SCHEMBL427632 0.77 MAPT (0.56) MAPTMEN1KMT2APOLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260034141-A1 METHODS AND COMPOSITIONS FOR TREATING MALIGNANT CANCERS 6J BIOTECHNOLOGY HONG KONG LTD (HK) 2026-02-05 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034141-A1 METHODS AND COMPOSITIONS FOR TREATING MALIGNANT CANCERS MCL1, GLI1, BECN1 MAPT 538/4885MEN1 5/4885KMT2A 2267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback